NASDAQ$MDGL
Madrigal Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Madrigal's financial performance and corporate advancements were reported.
Madrigal Pharmaceuticals reported its second quarter 2021 financial results, highlighting the progress made in clinical trials and commercial preparation for resmetirom. The company reached its enrollment goal for the MAESTRO-NASH trial and anticipates top-line results for its studies in the near future. Madrigal ended the quarter with $323.8 million in cash, cash equivalents, and marketable securities.
- Reached enrollment goal for MAESTRO-NASH trial to support 52-week liver biopsy accelerated approval portion.
- Top-line results expected by Q3 2022 for MAESTRO-NASH and by the end of 2021 for MAESTRO-NAFLD-1.
- Presented positive clinical results at EASL, highlighting the therapeutic value of resmetirom.
- Expanded leadership team with the appointment of Alex Howarth as CFO and Robert Waltermire as Chief Pharmaceutical Development Officer.
Headline financials
Revenue & EPS history
Madrigal · Revenue · Quarterly
$0
Forward guidance
Madrigal is focused on advancing the clinical development of resmetirom and preparing for its potential commercial launch. The company expects top-line data from the MAESTRO-NAFLD-1 study by the end of the year and from the MAESTRO-NASH study in the third quarter of 2022.
Tailwinds
- Advancing Phase 3 clinical trials for resmetirom.
- Preparing for potential U.S. launch of resmetirom.
- Building commercial resources and infrastructure.
- Developing a comprehensive product launch plan.
- Engaging with NASH physician and patient advocacy communities.
Headwinds
- Uncertainties related to clinical development of resmetirom.
- Enrollment uncertainties related to COVID-19 measures.
- Outcomes or trends from competitive studies.
- Risks of achieving potential benefits in studies with more patients.
- Uncertainties inherent in clinical testing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+7.8%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+48.0%
Q3 2024
Best reaction
-23.3%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -1.2% | -3.2% | |
| Q4 2025 | -11.1% | -10.5% | -10.2% | |
| Q3 2025 | +7.8% | +18.7% | +42.2% | |
| Q1 2025 | -1.9% | -11.6% | -17.6% | |
| Q4 2024 | +15.0% | +1.3% | +5.9% | |
| Q3 2024 | +48.0% | +56.4% | +52.0% | |
| Q2 2024 | -8.6% | -9.2% | -8.5% | |
| Q1 2024 | -11.7% | -12.9% | +2.5% | |
| Q4 2023 | -1.5% | +2.8% | +11.4% | |
| Q3 2023 | +3.6% | -5.5% | +61.1% | |
| Q2 2023 | -6.0% | -4.5% | +6.4% | |
| Q1 2023 | -5.4% | -5.2% | -12.8% | |
| Q4 2022 | -5.4% | -7.1% | -19.6% | |
| Q3 2022 | -6.7% | -10.1% | +12.8% | |
| Q2 2022 | +22.8% | +12.1% | +10.8% | |
| Q1 2022 | -0.2% | +1.8% | +15.0% | |
| Q4 2021 | +7.9% | +13.1% | +9.2% | |
| Q3 2021 | -0.5% | -1.6% | -16.6% | |
| Q2 2021 | +7.5% | +0.8% | -4.5% | |
| Q1 2021 | +0.7% | +2.3% | -22.0% | |
| Q4 2020 | -1.3% | -6.9% | -5.3% | |
| Q3 2020 | -6.8% | -2.2% | -10.9% | |
| Q2 2020 | -1.1% | -2.2% | +2.3% | |
| Q1 2020 | +2.9% | +25.1% | +27.6% | |
| Q4 2019 | -2.5% | +2.6% | -19.7% | |
| Q3 2019 | +0.1% | +7.9% | +22.1% | |
| Q2 2019 | +2.0% | +2.0% | +9.8% | |
| Q1 2019 | +0.2% | -3.4% | -8.0% | |
| Q4 2018 | -2.4% | +3.1% | -6.9% | |
| Q3 2018 | +5.2% | -7.8% | -39.7% | |
| Q2 2018 | -1.0% | -5.9% | -11.0% | |
| Q1 2018 | -0.0% | +2.2% | +138.3% | |
| Q4 2017 | -16.4% | -20.4% | -15.8% | |
| Q3 2017 | -0.2% | -5.7% | +84.7% | |
| Q2 2017 | -0.8% | +1.7% | +13.5% | |
| Q1 2017 | +2.1% | +4.5% | -0.3% | |
| Q4 2016 | -2.2% | -4.9% | +6.8% | |
| Q3 2016 | +5.3% | +2.4% | -1.4% | |
| Q2 2016 | +3.8% | +11.5% | +1.9% | |
| Q1 2016 | +10.5% | — | — | |
| Q4 2015 | -23.3% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | -3.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -6.1% | — | — | |
| Q3 2014 | +10.6% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | -10.1% | — | — | |
| Q3 2013 | +0.9% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.2% | — | — | |
| Q2 2012 | +0.3% | — | — | |
| Q1 2012 | -11.2% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q4 2009 | +0.2% | — | — | |
| Q3 2011 | +4.4% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q4 2010 | -10.1% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -6.1% | — | — | |
| Q2 2010 | -5.6% | — | — | |
| Q1 2010 | -16.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro